Investigation Into the Safety and Efficacy of ICG-Labeled Fluorescence Imaging Technology in Guiding the Resection of Bone and Soft Tissue Tumors

Not yet recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

May 25, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Bone NeoplasmsSoft Tissue Neoplasms
Interventions
DRUG

Indocyanine green (ICG)

Indocyanine green (ICG; National Drug Approval No. H20213567, Ruida Pharmaceuticals) is administered intravenously 24 hours preoperatively at a dose of 2 mg/kg. The drug is dissolved in 250 mL of normal saline using a light-protected infusion set and infused at a constant rate over 60 minutes. Alternatively, a 0.5 mg/kg dose may be administered via IV infusion 1-3 hours before surgery.

Trial Locations (1)

516008

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER

NCT06979115 - Investigation Into the Safety and Efficacy of ICG-Labeled Fluorescence Imaging Technology in Guiding the Resection of Bone and Soft Tissue Tumors | Biotech Hunter | Biotech Hunter